Astrazeneca PLC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
SCHEDULE: Vanguard Discloses AstraZeneca Stake
Vanguard Capital Management reports beneficial ownership of over 77.9 million shares, representing 5.02% of AstraZeneca PLC's common stock.
NYSE
AstraZeneca PLC and its subsidiary Alexion Pharmaceuticals, Inc. have disclosed a 7.8% beneficial ownership stake in Monopar Therapeutics Inc. as of December 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.6% Passive Stake in AstraZeneca PLC
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in AstraZeneca PLC as of March 31, 2025.
NYSE
AstraZeneca PLC and its subsidiary AstraZeneca AB have filed an amended Schedule 13G, reporting a 1.1% passive beneficial ownership stake in Conduit Pharmaceuticals Inc.